Table 1.
Developer | Type | Doses | Participants/P3 | Study Location | Efficacy/US | EUA Date |
---|---|---|---|---|---|---|
Pfizer-BioNTech | mRNA | 2 | 43,548 | International | 95% | 11 December 2020 |
Moderna-NIAID | mRNA | 2 | 34,420 | United States | 94% | 18 December 2020 |
Johnson&Johnson-Janssen | Viral vector | 1 | 43,783 | International | 72% | 27 February 2021 |
EUA (Emergency Use Authorization), NIAID (National Institute of Allergy and Infectious Diseases) P3 (Phase III clinical trials).